

# Jessica N Mcalpine

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/480137/publications.pdf>

Version: 2024-02-01

150  
papers

11,743  
citations

20759

60  
h-index

31759

101  
g-index

151  
all docs

151  
docs citations

151  
times ranked

12310  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention. <i>JAMA Network Open</i> , 2022, 5, e2147343.	2.8	41
2	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases. <i>Gynecologic Oncology</i> , 2022, 165, 376-384.	0.6	20
3	Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification. <i>Gynecologic Oncology</i> , 2022, 165, 201-214.	0.6	18
4	Endometrial cancer. <i>Lancet, The</i> , 2022, 399, 1412-1428.	6.3	324
5	Differentiated Exophytic Vulvar Intraepithelial Lesions: Case Reports and Review of Literature. <i>Journal of Lower Genital Tract Disease</i> , 2022, 26, 283-286.	0.9	1
6	BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors. <i>British Journal of Cancer</i> , 2022, 127, 488-499.	2.9	6
7	Opportunistic salpingectomy between 2011 and 2016: a descriptive analysis. <i>CMAJ Open</i> , 2022, 10, E466-E475.	1.1	5
8	Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape. <i>Cancer</i> , 2022, 128, 2853-2857.	2.0	9
9	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 217-228.	1.1	12
10	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. <i>Modern Pathology</i> , 2021, 34, 508-518.	2.9	40
11	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	2.9	21
12	The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer collaboration study. <i>Human Pathology</i> , 2021, 109, 80-91.	1.1	22
13	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. <i>Human Pathology</i> , 2021, 108, 1-11.	1.1	8
14	The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110359.	1.4	54
15	p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 907-913.	1.2	37
16	Evaluation of treatment effects in patients with endometrial cancer and <i>POLE</i> mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021, 127, 2409-2422.	2.0	62
17	Reply to Survival analysis and treatment effects in patients with endometrial cancer and <i>POLE</i> mutations. <i>Cancer</i> , 2021, 127, 4308-4309.	2.0	1
18	Endoscopic optical coherence tomography and autofluorescence imaging of the endocervical canal for cervical cancer detection. , 2021, , .		2

#	ARTICLE	IF	CITATIONS
19	From biobank and data silos into a data commons: convergence to support translational medicine. <i>Journal of Translational Medicine</i> , 2021, 19, 493.	1.8	11
20	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 552-560.	0.6	49
21	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 537-545.	0.9	25
22	Interpretation of somatic <i>POLE</i> mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020, 250, 323-335.	2.1	203
23	Clinicopathological and molecular characterisation of a multiple classifier™ endometrial carcinomas. <i>Journal of Pathology</i> , 2020, 250, 312-322.	2.1	205
24	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	1.2	29
25	Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. <i>Journal of Pathology</i> , 2020, 252, 201-214.	2.1	31
26	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5400-5410.	3.2	41
27	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	3.0	32
28	Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 783-788.	1.2	12
29	FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes. <i>Clinical Cancer Research</i> , 2020, 26, 4569-4580.	3.2	10
30	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020, 26, 4402-4413.	3.2	21
31	Improving response to progestin treatment of low-grade endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1811-1823.	1.2	21
32	Examining indicators of early menopause following opportunistic salpingectomy: a cohort study from British Columbia, Canada. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 221.e1-221.e11.	0.7	28
33	Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 100-106.	1.2	29
34	Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. <i>Gynecologic Oncology</i> , 2020, 158, 3-11.	0.6	78
35	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. <i>Modern Pathology</i> , 2020, 33, 1595-1605.	2.9	103
36	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. <i>Modern Pathology</i> , 2020, 33, 1649-1659.	2.9	17

#	ARTICLE	IF	CITATIONS
37	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. PLoS ONE, 2020, 15, e0240412.	1.1	1
38	Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstetrics and Gynecology Science, 2020, 63, 417-431.	0.6	48
39	Title is missing!. , 2020, 15, e0240412.		0
40	Title is missing!. , 2020, 15, e0240412.		0
41	Title is missing!. , 2020, 15, e0240412.		0
42	Title is missing!. , 2020, 15, e0240412.		0
43	Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. Genome Biology, 2019, 20, 210.	3.8	171
44	OVQUEST â€“ Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors. Gynecologic Oncology, 2019, 155, 126-134.	0.6	26
45	Precision medicine in endometrial cancer. Gynecologic Oncology, 2019, 154, 451-453.	0.6	9
46	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
47	Probabilistic cell-type assignment of single-cell RNA-seq for tumor microenvironment profiling. Nature Methods, 2019, 16, 1007-1015.	9.0	241
48	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. Human Pathology, 2019, 92, 39-47.	1.1	9
49	Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer. Gynecologic Oncology, 2019, 154, 124-130.	0.6	72
50	Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. Gynecologic Oncology, 2019, 153, 487-495.	0.6	72
51	Causes of death among women with epithelial ovarian cancer by length of survival post-diagnosis: a population-based study in British Columbia, Canada. International Journal of Gynecological Cancer, 2019, 29, 593-598.	1.2	6
52	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. Clinical Cancer Research, 2019, 25, 2537-2548.	3.2	101
53	Submillimeter diameter rotary-pullback fiber-optic endoscope for narrowband red-green-blue reflectance, optical coherence tomography, and autofluorescence in vivo imaging. Journal of Biomedical Optics, 2019, 25, 1.	1.4	9
54	Authors' Reply. Journal of Pathology, 2018, 245, 251-251.	2.1	0

#	ARTICLE	IF	CITATIONS
55	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. <i>American Journal of Surgical Pathology</i> , 2018, 42, 561-568.	2.1	214
56	The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. <i>Journal of Pathology</i> , 2018, 244, 538-549.	2.1	172
57	Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. <i>Annals of Oncology</i> , 2018, 29, 1180-1188.	0.6	416
58	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. <i>BMC Cancer</i> , 2018, 18, 254.	1.1	19
59	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. <i>BMC Cancer</i> , 2018, 18, 347.	1.1	67
60	Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1624-1630.	1.2	8
61	Changing Clinical Practice. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1101-1107.	1.2	6
62	Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. <i>BMC Cancer</i> , 2018, 18, 1039.	1.1	31
63	Does MMR status in endometrial cancer influence response to adjuvant therapy?. <i>Gynecologic Oncology</i> , 2018, 151, 76-81.	0.6	25
64	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. <i>British Journal of Cancer</i> , 2018, 119, 480-486.	2.9	86
65	Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 172.e1-172.e8.	0.7	27
66	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , 2018, 173, 1755-1769.e22.	13.5	261
67	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. <i>Cancer</i> , 2017, 123, 802-813.	2.0	552
68	Human papillomavirus (<sc>HPV</sc>) independent vulvar squamous cell carcinoma has a worse prognosis than <sc>HPV</sc> associated disease: a retrospective cohort study. <i>Histopathology</i> , 2017, 71, 238-246.	1.6	92
69	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017, 49, 856-865.	9.4	220
70	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. <i>American Journal of Surgical Pathology</i> , 2017, 41, 245-252.	2.1	81
71	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
72	Foreword. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 685-685.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Risk-reducing Surgery in Women at Low Lifetime Risk of Developing Ovarian Carcinoma: Opportunistic Salpingectomy. <i>Clinical Obstetrics and Gynecology</i> , 2017, 60, 758-770.	0.6	7
74	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 279-293.	1.3	70
75	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. <i>Journal of Pathology</i> , 2017, 243, 26-36.	2.1	69
76	HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 507-516.	0.9	50
77	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 126-136.	1.2	29
78	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	0.8	23
79	Boosted Tree Classifier for in Vivo Identification of Early Cervical Cancer using Multispectral Digital Colposcopy. , 2017, , .		1
80	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e247-e257.	1.8	9
81	p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases. <i>International Journal of Gynecological Pathology</i> , 2016, 35, 385-393.	0.9	70
82	Endometrial cancer: Not your grandmother's cancer. <i>Cancer</i> , 2016, 122, 2787-2798.	2.0	132
83	Opportunistic Salpingectomy: We Chose to Act, Not Wait. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 425-427.	0.3	11
84	Subpubic Cartilaginous Cyst: A Rare Sub-Clitoral Mass. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 102-103.	0.3	2
85	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. <i>Nature Genetics</i> , 2016, 48, 758-767.	9.4	287
86	Clonal genotype and population structure inference from single-cell tumor sequencing. <i>Nature Methods</i> , 2016, 13, 573-576.	9.0	108
87	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016, 141, 559-563.	0.6	25
88	Diffuse optical microscopy for quantification of depth-dependent epithelial backscattering in the cervix. <i>Journal of Biomedical Optics</i> , 2016, 21, 066001.	1.4	10
89	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. <i>Gynecologic Oncology</i> , 2016, 143, 46-53.	0.6	153
90	La salpingectomie opportuniste : Nous choisissons d'agir, pas d'attendre. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2016, 38, 428-431.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Endometrial Carcinomas with <i>POLE</i> Exonuclease Domain Mutations Have a Favorable Prognosis. <i>Clinical Cancer Research</i> , 2016, 22, 2865-2873.	3.2	139
92	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016, 141, 148-154.	0.6	34
93	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 302-314.	2.9	123
94	Histopathological features of endometrial carcinomas associated with <i>POLE</i> mutations: implications for decisions about adjuvant therapy. <i>Histopathology</i> , 2016, 68, 916-924.	1.6	65
95	Fluorescence confocal endomicroscopy of the cervix: pilot study on the potential and limitations for clinical implementation. <i>Journal of Biomedical Optics</i> , 2016, 21, 126011.	1.4	25
96	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e247-e257.	1.8	8
97	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 517-527.	0.9	15
98	Costs and Benefits of Opportunistic Salpingectomy as an Ovarian Cancer Prevention Strategy. <i>Obstetrics and Gynecology</i> , 2015, 125, 338-345.	1.2	106
99	Expanding the Morphologic Spectrum of Differentiated VIN (dVIN) Through Detailed Mapping of Cases With p53 Loss. <i>American Journal of Surgical Pathology</i> , 2015, 39, 52-60.	2.1	71
100	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1187-1193.	1.2	31
101	In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 173-185.	1.3	70
102	Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2015, 137, 306-310.	0.6	170
103	The more tumors change, the more they stay tame: Do T cells keep <i>POLE</i> ultramutated endometrial carcinomas in check?. <i>Gynecologic Oncology</i> , 2015, 138, 1-2.	0.6	14
104	Clinical and pathological characterization of endometrial cancer in young women: Identification of a cohort without classical risk factors. <i>Gynecologic Oncology</i> , 2015, 138, 141-146.	0.6	29
105	Canadian high risk endometrial cancer (CHREC) consortium: Analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015, 139, 268-274.	0.6	50
106	Opportunistic salpingectomy for ovarian cancer prevention. <i>Gynecologic Oncology Research and Practice</i> , 2015, 2, 5.	3.6	28
107	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. <i>BMC Cancer</i> , 2015, 15, 415.	1.1	116
108	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 671-676.	1.1	82

#	ARTICLE	IF	CITATIONS
109	The Fallopian Tube as the Origin of High Grade Serous Ovarian Cancer: Review of a Paradigm Shift. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 133-140.	0.3	70
110	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. <i>Genome Research</i> , 2014, 24, 1881-1893.	2.4	322
111	Pelvic Inflammation and the Pathogenesis of Ovarian Cancer: A Cohort Study. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1406-1413.	1.2	15
112	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. <i>Modern Pathology</i> , 2014, 27, 128-134.	2.9	218
113	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 210, 471.e1-471.e11.	0.7	236
114	Quality of Life Research in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1686-1692.	1.2	19
115	Determinants of Quality of Life in Ovarian Cancer Survivors: A Pilot Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2014, 36, 708-715.	0.3	30
116	Absence of BRCA/FMR1 Correlations in Women with Ovarian Cancers. <i>PLoS ONE</i> , 2014, 9, e102370.	1.1	8
117	Uterine adenosarcomas: A dual-institution update on staging, prognosis and survival. <i>Gynecologic Oncology</i> , 2013, 131, 634-639.	0.6	36
118	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with <sc>HER2</sc> targeting in 19% of carcinomas. <i>Journal of Pathology</i> , 2013, 229, 111-120.	2.1	169
119	Specimen Quality Evaluation in Canadian Biobanks Participating in the COEUR Repository. <i>Biopreservation and Biobanking</i> , 2013, 11, 83-93.	0.5	35
120	Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1421-1432.	2.1	115
121	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. <i>Journal of Pathology</i> , 2013, 231, 21-34.	2.1	357
122	Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. <i>Obstetrics and Gynecology</i> , 2013, 121, 14-24.	1.2	134
123	Risk-Reducing Salpingectomy in Canada: A Survey of Obstetrician-Gynaecologists. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 627-634.	0.3	34
124	Prophylactic Salpingectomy and Delayed Oophorectomy as an Alternative for BRCA Mutation Carriers. <i>Obstetrical and Gynecological Survey</i> , 2013, 68, 442-444.	0.2	0
125	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	2.9	151
126	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 929-934.	3.3	239



#	ARTICLE	IF	CITATIONS
127	Germline BRCA1 and BRCA2 Mutations in Ovarian Cancer. <i>Obstetrics and Gynecology</i> , 2012, 120, 235-240.	1.2	111
128	It Sounded Like a Good Idea at the Time. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 1127-1130.	0.3	14
129	Risk-Reducing Bilateral Salpingo-Oophorectomy and Sexual Health: A Qualitative Study. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012, 34, 172-178.	0.3	14
130	Use of mutation profiles to refine the classification of endometrial carcinomas. <i>Journal of Pathology</i> , 2012, 228, 20-30.	2.1	261
131	A brief mindfulness-based cognitive behavioral intervention improves sexual functioning versus wait-list control in women treated for gynecologic cancer. <i>Gynecologic Oncology</i> , 2012, 125, 320-325.	0.6	222
132	The role of the fallopian tube in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 296-306.	0.3	77
133	Frequency of Known Gene Rearrangements in Endometrial Stromal Tumors. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1364-1372.	2.1	128
134	Survivorship as an Element of Clinical Trials in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 788-792.	1.2	3
135	Autofluorescence imaging can identify preinvasive or clinically occult lesions in fallopian tube epithelium: A promising step towards screening and early detection. <i>Gynecologic Oncology</i> , 2011, 120, 385-392.	0.6	50
136	The significance of surgical staging in intermediate-risk endometrial cancer. <i>Gynecologic Oncology</i> , 2011, 122, 50-54.	0.6	13
137	Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts. <i>Clinical Cancer Research</i> , 2011, 17, 783-791.	3.2	67
138	Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. <i>PLoS ONE</i> , 2011, 6, e21121.	1.1	71
139	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. <i>BMC Cancer</i> , 2009, 9, 433.	1.1	175
140	The incidence and risk factors associated with postoperative delirium in geriatric patients undergoing surgery for suspected gynecologic malignancies. <i>Gynecologic Oncology</i> , 2008, 109, 296-302.	0.6	47
141	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. <i>Gynecologic Oncology</i> , 2008, 110, 256-264.	0.6	59
142	Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. <i>Gynecologic Oncology</i> , 2008, 110, 360-364.	0.6	33
143	The Multifunctional Protein Glyceraldehyde-3-Phosphate Dehydrogenase Is Both Regulated and Controls Colony-Stimulating Factor-1 Messenger RNA Stability in Ovarian Cancer. <i>Molecular Cancer Research</i> , 2008, 6, 1375-1384.	1.5	96
144	Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease†. <i>Gynecologic Oncology</i> , 2007, 105, 211-217.	0.6	159

#	ARTICLE	IF	CITATIONS
145	Improved Survival in Surgical Stage I Patients With Uterine Papillary Serous Carcinoma (UPSC) Treated With Adjuvant Platinum-Based Chemotherapy. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, 27-29.	0.2	0
146	Atypical presentations of carboplatin hypersensitivity reactions: Characterization and management in patients with gynecologic malignancies. <i>Gynecologic Oncology</i> , 2006, 103, 288-292.	0.6	18
147	Upstaging based solely on positive peritoneal washing does not affect outcome in endometrial cancer. <i>Modern Pathology</i> , 2005, 18, 673-680.	2.9	72
148	Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. <i>Gynecologic Oncology</i> , 2005, 98, 242-248.	0.6	39
149	Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. <i>Gynecologic Oncology</i> , 2005, 98, 353-359.	0.6	192
150	Pelvic arterial embolization for control of obstetric hemorrhage: A five-year experience. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 1454-1460.	0.7	266